INCREDIBLE WEEK! Still buzzing from our presentation at ASBRS2025 in Las Vegas where we unveiled our game-changing clinical findings! 💫
We’re thrilled to share that we successfully showcased how our innovative Digistain® technology compares to Oncotype DX in predicting metastasis-free survival for early-stage HR+ breast cancer patients. The reception from the oncology community was phenomenal!
For those who missed it, we’ll be sharing more detailed findings in the coming weeks. The future of breast cancer prognostics is evolving rapidly, and Digistain® is proving to be a significant part of that story!
